- Home
- ASIC vs MNMD Comparison
ASIC vs MNMD Comparison
Compare ASIC & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASIC
- MNMD
- Stock Information
- Founded
- ASIC 2018
- MNMD 2019
- Country
- ASIC United States
- MNMD United States
- Employees
- ASIC N/A
- MNMD N/A
- Industry
- ASIC Property-Casualty Insurers
- MNMD Pharmaceuticals and Biotechnology
- Sector
- ASIC Finance
- MNMD Health Care
- Exchange
- ASIC Nasdaq
- MNMD Nasdaq
- Market Cap
- ASIC 1.1B
- MNMD 960.2M
- IPO Year
- ASIC 2025
- MNMD N/A
- Fundamental
- Price
- ASIC $18.92
- MNMD $12.41
- Analyst Decision
- ASIC Strong Buy
- MNMD Strong Buy
- Analyst Count
- ASIC 4
- MNMD 7
- Target Price
- ASIC $25.50
- MNMD $26.71
- AVG Volume (30 Days)
- ASIC 213.1K
- MNMD 2.1M
- Earning Date
- ASIC 10-22-2025
- MNMD 10-31-2025
- Dividend Yield
- ASIC N/A
- MNMD N/A
- EPS Growth
- ASIC N/A
- MNMD N/A
- EPS
- ASIC 0.17
- MNMD N/A
- Revenue
- ASIC $405,657,000.00
- MNMD N/A
- Revenue This Year
- ASIC $16.14
- MNMD N/A
- Revenue Next Year
- ASIC $47.06
- MNMD N/A
- P/E Ratio
- ASIC $109.21
- MNMD N/A
- Revenue Growth
- ASIC 42.48
- MNMD N/A
- 52 Week Low
- ASIC $16.35
- MNMD $4.70
- 52 Week High
- ASIC $25.30
- MNMD $14.30
- Technical
- Relative Strength Index (RSI)
- ASIC N/A
- MNMD 55.54
- Support Level
- ASIC N/A
- MNMD $11.88
- Resistance Level
- ASIC N/A
- MNMD $12.76
- Average True Range (ATR)
- ASIC 0.00
- MNMD 0.89
- MACD
- ASIC 0.00
- MNMD -0.10
- Stochastic Oscillator
- ASIC 0.00
- MNMD 31.02
About ASIC Ategrity Specialty Insurance Company Holdings Common Stock
Ategrity Specialty Insurance Co Holdings Formerly Ategrity Specialty Holdings LLC is a specialty insurance company dedicated to providing excess and surplus products to small to medium-sized businesses across the United States. It offers property and casualty insurance solutions tailored to meet the needs of SMBs. The company focuses on are Real Estate, Hospitality, Construction, and Retail.
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).